Shuttle Pharmaceuticals Enters Material Agreement, Completes Acquisition

Ticker: SHPH · Form: 8-K · Filed: Nov 26, 2025 · CIK: 1757499

Shuttle Pharmaceuticals Holdings, Inc. 8-K Filing Summary
FieldDetail
CompanyShuttle Pharmaceuticals Holdings, Inc. (SHPH)
Form Type8-K
Filed DateNov 26, 2025
Risk Levelmedium
Pages4
Reading Time4 min
Key Dollar Amounts$0.00001, $3,000,000, $2,000,000, $1,000,000
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, acquisition, equity-sale

TL;DR

Shuttle Pharma inked a big deal, closed an acquisition, and sold some stock. Big moves happening!

AI Summary

Shuttle Pharmaceuticals Holdings, Inc. announced on November 26, 2025, that it entered into a material definitive agreement. The company also reported the completion of an acquisition or disposition of assets and disclosed unregistered sales of equity securities. Specific details regarding the agreement, acquisition, and sales were filed on this Form 8-K.

Why It Matters

This filing indicates significant corporate actions, including a new agreement and asset transactions, which could impact the company's strategic direction and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements, acquisitions, and unregistered equity sales can introduce significant financial and operational risks.

Key Players & Entities

  • Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
  • November 26, 2025 (date) — Date of Report
  • November 20, 2025 (date) — Earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Gaithersburg, MD (location) — Principal executive offices

FAQ

What is the nature of the material definitive agreement entered into by Shuttle Pharmaceuticals?

The filing indicates a material definitive agreement was entered into, but specific details are not provided in the provided text.

What type of acquisition or disposition of assets was completed?

The filing confirms the completion of an acquisition or disposition of assets, but the specifics of the transaction are not detailed in the provided text.

When did the earliest event reported in this 8-K filing occur?

The earliest event reported in this 8-K filing occurred on November 20, 2025.

What is Shuttle Pharmaceuticals Holdings, Inc.'s state of incorporation?

Shuttle Pharmaceuticals Holdings, Inc. is incorporated in Delaware.

What are the principal executive offices of Shuttle Pharmaceuticals Holdings, Inc.?

The principal executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.

Filing Stats: 1,050 words · 4 min read · ~4 pages · Grade level 12.4 · Accepted 2025-11-26 12:28:39

Key Financial Figures

  • $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
  • $3,000,000 — of: (a) a one-time cash contribution of $3,000,000, paid on the Closing Date; (ii) a first
  • $2,000,000 — econd installment contribution equal to $2,000,000, payable on the one year anniversary of
  • $1,000,000 — t to receive two contributions equal to $1,000,000 each by the achievement of the followin

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: November 26, 2025 By: /s/ Christopher Cooper Name: Christopher Cooper Title: Interim Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.